NCT07266142 Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker
| NCT ID | NCT07266142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Skin Cancer, Non-Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,500 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2050-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,500 participants in total. It began in 2025-11-17 with a primary completion date of 2050-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls. The main questions it aims to answer are: * To create a biobank with samples of human body material (HBM): blood (serum/plasma/DNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls. * To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols). If there is a comparison group: Not applicable (umbrella protocol for collection only). Participants will: * Share demographics, medical and surgical history, risk factors. * Complete Cancer Worry Scale questionnaire. * Provide biological samples: * Blood samples (serum, plasma, DNA). * Tissue samples (residual tissue or additional biopsy if consented).
Eligibility Criteria
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Adult subjects (\>18 years of age) at time of enrolment. * Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls. * Adult subjects able and willing to provide informed consent. Exclusion Criteria: * Subjects unable or not willing to provide informed consent. * Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07266142 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Skin Cancer, Non-Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07266142 currently recruiting?
Yes, NCT07266142 is actively recruiting participants. Contact the research team at annemiek.leeman@uzleuven.be for enrollment information.
Where is the NCT07266142 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT07266142 clinical trial?
NCT07266142 is sponsored by Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 7,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.